// App-Quantinova.ai

: The Efficacy and Safety of Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease in Chinese Patients: Systematic Review and Meta-Analysis

Researchers

Presenter

  • Xu Yang

Principal Investigators

  • Zhongnan Wang

  • Depei Wu

Medical Centers

  • Beijing Novartis Pharma, Beijing, China

  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

Biomarkers

  • N/A

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Observational

  • Tolerability

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved